NTL Healthcare, a leading company specializing
in women's cancer, has announced its
participation in the "MEDICA 2023" exhibition,
which will be held in Dusseldorf, Germany
from November 13th to 16th for four days.

 

MEDICA is the world's largest medical device
exhibition, and this year, about 50,000
companies from around the world will
participate to showcase new products and
technologies in various fields, including
diagnostic medicine, digital healthcare,
medical imaging devices, laboratory technology,
mobile healthcare, physiotherapy/orthopedic
surgery technology, and medical consumables.
About 300 domestic companies will participate,
and a total of seven Korean pavilions
will be operated.

 

MEDICA consists of seven forums,
three conferences, and two special shows,
which will focus on medical device trends
such as AI, big data, machine learning,
robotics, sustainability, health metaverse,
and digital therapy.

 

NTL Healthcare has been selected as a
supported company for excellent overseas
exhibition participation by K-MEDI Hub
(Daegu-Gyeongbuk Medical Innovation
Foundation) and will operate a booth at
"MEDICA 2023". In particular, it will
showcase the excellence of their
CerviCARE® AI, an artificial intelligence
(AI) cervical cancer screening system,
through direct demonstrations to overseas
buyers at 'MEDICA 2023.

 

CerviCARE AI boasts a high accuracy

based on cervical images big data

accumulated over 27 years since 1996.

It can classify cervical cancer test results

as normal and abnormal within 5 seconds (1).
In addition, it can distinguish morphological
abnormalities of the cervix and mark the
affected areas, supporting clinical decisions
in determining further treatment directions.
NTL explains that demand for the product is
steadily increasing in Vietnam, Thailand,
Brazil, Mongolia, and other countries.

 

Taehee Kim, CEO of NTL Healthcare, said,
"Recently, we were selected as an outstanding
company in the 2023 Small and Medium-sized
Enterprise Innovation Contest and received
the Minister of Small and Venture Business
Award, confirming not only our technological
capabilities but also our business innovation.
As a result of a successful overseas debut in
Vietnam, Mongolia, Thailand, Brazil, and other
countries, I expect NTL to take more aggressive
wings for overseas expansion through 'MEDICA
2023.' I look forward to the day when women
in areas with vulnerable medical infrastructure
can conveniently and safely receive cervical
cancer screening through CerviCARE AI,
regardless of national borders and regions.

 

 

 

Ref: 1) Test Report, Standard Bank, 2023